Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Interferon alpha oral lozenge
Interferon alpha lozenge · 1 trial · 4 indications
Disease progression was determined by comparing results of the High Resolution Computed Tomography(HRCT) and pulmonary function at one year to the baseline HRCT \& pulmonary function. The same radiologist did the comparsion for all subjects.
| Name | Type | Description |
|---|---|---|
| Interferon alpha oral lozenge | DRUG | dose form - oral lozenge dose - 150 International Units (IU) frequency - 3 times a day duration - at least 1 year |
Inclusion Criteria: * The only subjects to be included in this study are those diagnosed with Idiopathic Pulmonary Fibrosis with diagnosis based on the criteria published by the American Thoracic Society in the International Consensus Statement. 1. Exclusion of other known causes of interstitial...
Interferon alpha lozenge is an orally administered formulation of interferon alpha developed by Ainos, Inc. under the ticker AIMD. It is being studied in respiratory tract diseases, including interstitial lung disease and pulmonary fibrosis. The lozenge is a small molecule modality given by mouth rather than by injection.
Interferon alpha lozenge is being developed for respiratory tract diseases. Its completed Phase 2 trial enrolled patients with idiopathic pulmonary fibrosis, a form of interstitial lung disease. The study was conducted in the United States and included adults aged 50 years and older.
Interferon alpha lozenge is developed by Ainos, Inc., which trades under the ticker AIMD. The company is the sponsor of the oral interferon alpha program in respiratory tract diseases.
Interferon alpha lozenge is in Phase 2 development. It is investigational and has not been approved by the FDA. One Phase 2 trial has been completed, and no trials are currently active.
Interferon alpha lozenge has been studied in one completed Phase 2 trial, NCT01442779, titled Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis. The trial enrolled 18 participants in the United States, was uncontrolled, and was not randomized or double blinded.
Yes, interferon alpha lozenge is also known as interferon alpha oral lozenge. Both names refer to the same Ainos, Inc. oral interferon alpha product being studied in respiratory tract diseases.